BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $14,225.60 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 523 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $27.20, for a total transaction of $14,225.60. Following the sale, the executive vice president now owns 283,919 shares of the company’s stock, valued at approximately $7,722,596.80. The trade was a 0.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

BioLife Solutions Trading Up 1.1 %

BLFS stock traded up $0.31 during midday trading on Friday, hitting $27.47. The stock had a trading volume of 200,092 shares, compared to its average volume of 388,973. The firm has a market cap of $1.27 billion, a PE ratio of -25.92 and a beta of 1.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions, Inc. has a 12-month low of $11.91 and a 12-month high of $28.88. The company’s 50-day moving average price is $24.19 and its 200 day moving average price is $23.19.

Institutional Trading of BioLife Solutions

Several hedge funds and other institutional investors have recently bought and sold shares of BLFS. Stifel Financial Corp grew its stake in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 670 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of BioLife Solutions by 4.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after buying an additional 700 shares during the period. GAMMA Investing LLC grew its stake in shares of BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of BioLife Solutions by 5.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 753 shares during the period. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in shares of BioLife Solutions during the 3rd quarter valued at $28,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BLFS. HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Northland Securities raised their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, TD Cowen raised their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $27.50.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.